Fidelity Investments
NVCT icon

Fidelity Investments’s Nuvectis Pharma NVCT Stock Holding History

Fidelity Investments’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Buy
8,061
+493
+7% +$5.52K ﹤0.01% 3798
2026
Q1 		$58.5K Buy
7,568
+358
+5% +$3.07K ﹤0.01% 4059
2025
Q4 		$54.4K Buy
7,210
+7,143
+10,661% +$46.6K ﹤0.01% 4063
2025
Q3 		$403 Buy
67
+62
+1,240% +$426 ﹤0.01% 5103
2025
Q2 		$37 Buy
+5
New +$45 ﹤0.01% 5198
2024
Q4 		– Sell
-402
Closed -$2.53K – 5733
2024
Q3 		$2.53K Sell
402
-569
-59% -$3.74K ﹤0.01% 4756
2024
Q2 		$6.15K Buy
971
+536
+123% +$3.64K ﹤0.01% 4484
2024
Q1 		$3.57K Buy
435
+433
+21,650% +$3.68K ﹤0.01% 4597
2023
Q4 		$17 Sell
2
-5
-71% -$45 ﹤0.01% 5246
2023
Q3 		$90 Sell
7
-17
-71% -$246 ﹤0.01% 4871
2023
Q2 		$383 Buy
+24
New +$383 ﹤0.01% 4847

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Fidelity Investments's NVCT Position: Q2 2026 in Review

Fidelity Investments increased its Nuvectis Pharma (NVCT) stake by 6.5% in Q2 2026, buying an estimated $5.52K and bringing the position to 8,061 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #3798.

Fidelity Investments first reported a position in NVCT in Q2 2023 and has held it in 11 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Fidelity Investments held 8,061 shares of Nuvectis Pharma worth $148K as of Q2 2026.
  • Fidelity Investments bought 493 Nuvectis Pharma shares in Q2 2026, an estimated $5.52K.
  • Nuvectis Pharma made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3798 holding.
  • Fidelity Investments first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 11 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.